Topic: Growth Stocks

Beckman Coulter Inc. $70 – New York symbol BEC

BECKMAN COULTER INC. $70 (New York symbol BEC; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 62.9 million; Market cap: $4.4 billion; WSSF Rating: Average) makes lab equipment that doctors and medical researchers use to detect substances in bodily fluids.

Beckman is a long-time favorite of ours, mainly because its automated systems help its customers cut the cost of routine tests. The company also continues to profit from a change in the way it leases its equipment. The switch helped make its products more affordable. As well, a broader customer base has spurred more demand for replenishible supplies and maintenance services. Beckman now gets close to 80% of its total revenue from selling supplies. These recurring revenue streams cut its risk.

In the three months ended March 31, 2008, Beckman’s revenue grew 19.1%, to $730.5 million from $613.6 million a year earlier. If you exclude the positive impact of currency exchange rates, revenue rose 14.8%. However, earnings before unusual items grew just 4.6%, to $0.68 a share (total $44.0 million) from $0.65 a share ($41.4 million). The slower growth was due to more sales of lower-margin equipment.

Beckman recently acquired the rights to certain Hepatitis C virus-testing research from Siemens. The company plans to use this information to develop a new blood test for the virus. In connection with this purchase, Beckman will record a charge of $12 million in the second quarter of 2008.

Beckman spends roughly 10% of its revenue of $44.75 a share on research. New products from this spending should lift its 2008 earnings to $3.61 a share. The stock trades at 19.4 times that figure. The $0.68 dividend yields 1.0%.

Beckman Coulter is a buy

Comments are closed.